Assay of Cefotaxime
Journal of Medical Sciences · 01.01.2009 · 8 (1) · 41-43
DOI: 10.51984/rxr3cz61 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Sciences, online erschienen am 01.01.2009. Verfasst von Salma Elkudafi und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Editorial summary prepared for the online archive; the original print article was published without an abstract.This study assayed the active ingredient content of two brands of cefotaxime powder for parenteral use that were in use at Algala Paediatric Hospital, Tripoli, to find out whether a substandard product could be contributing to the cefotaxime resistance reported there. The content was determined by HPLC according to the British Pharmacopoeia 2001 monograph for cefotaxime injection, after optimising the methanol concentration of the mobile phase (318 ml in 1000 ml gave a retention time of about 6 minutes, a resolution of 3.6 and a symmetry factor of 1.3).The mean content was 105.2% (SD 1.26) for the first product and 98.8% (SD 2.02) for the second, both within the pharmacopoeial limits of 90.0–110.0% of the stated amount. The authors conclude that low potency of the products does not explain the resistance, and they recommend further study of previously used products, bioavailability and the hospital’s antibiotic policy.
Zitieren
APA
Elkudafi, S., Elmusrati, Hweta, A., & Alagaly, E. (2009). Assay of Cefotaxime. Journal of Medical Sciences, 8(1), 41-43. https://doi.org/10.51984/rxr3cz61
Vancouver
Elkudafi S, Elmusrati, Hweta A, Alagaly E. Assay of Cefotaxime. Journal of Medical Sciences. 2009;8(1):41-43. doi:10.51984/rxr3cz61
BibTeX
@article{Elkudafi2009,
author = {Elkudafi, Salma and Elmusrati and Hweta, Arwa and Alagaly, Esra},
title = {Assay of Cefotaxime},
journal = {Journal of Medical Sciences},
year = {2009},
volume = {8},
number = {1},
pages = {41--43},
doi = {10.51984/rxr3cz61}
}
EUVIMED